Dendrite Clinical Systems and the Society for Cardiothoracic surgery (SCTS) have published a new report that demonstrates importance collecting and analysing data from thoracic surgery. The report states that a large increase in thoracoscopic (VATS) resections is responsible for most of the recent increase in lung cancer surgery, rising from 749 cases in 2010-2011 to 2,753 in 2014-2015, an increase of more than 3.5 times.
Dendrite Clinical Systems is to install its Intellect System to track outcomes of cardiothoracic surgery at St George’s Hospital, Tooting, London, UK. The company’s data capture software currently supports approximately 85% of cardiac units in the UK. 
Dendrite Clinical Systems and Waldenström’s Macroglobulinaemia United Kingdom Charity have published the First UK Waldenström’s Macroglobulinaemia Registry Report 2018 – the first report of its kind in the world. 
Dendrite Clinical Systems, the publisher of Bariatric News, is pleased to announce issue 38 of the newspaper is now available to view/download. The newspaper reports on research, technology, events and policy in the bariatric specialty, the latest clinical studies, policy changes and product news, the latest meetings and events, interviews prominent bariatric experts, and host debates between specialists on controversial topics.
Dendrite Clinical Systems and the British Society for Allergy & Clinical Immunology (BSACI) have launched the British Registry for Immunotherapy (BRIT), a web-based patient registry that records immunotherapy treatment of patients under the care of BSACI consultants practicing in the UK.
Dendrite Clinical Systems, under the auspices of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), has published the Fourth IFSO Global Registry Report (2018) at the federation’s XXIII World Congress in Dubai, UAE. The latest report features data from more than 50 countries on over 394,000 operations including baseline obesity-related disease, operation types, operative outcomes and disease status after bariatric/metabolic surgery.
Researchers at the University College London and University College London Hospitals NHS Foundation Trust), London, UK, have reported that the vast majority of participants with new onset loss of smell were positive for COVID19, and this acute loss of sense of smell needs to be considered globally as a criterion for self-isolation, testing and contact tracing in order to contain the spread of COVID-19.
The Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste (FORECAST) study, led by Professor Rachel Batterham, is a unique observational cohort study looked at two cohorts of patients presenting with COVID-19. The study utilised Dendrite Clinical Systems’ innovative Patient-Reported Outcome Measures (PROMs) software.
“We are delighted that our PROMs software proved to be highly effective in validating participants eligibility for the study and capturing and recording their data,” said Dr Peter Walton, Managing Director of Dendrite Clinical Systems. “The outcomes from the FORECAST study clearly demonstrate that the loss of smell and/or taste are highly-reliable indicators that someone is likely to have Covid-19. These finding could help dramatically reduce the spread of this pandemic and will help direct global healthcare practice in the fight against COVID19.”
PROMS software
Using the unique Covid Symptom Study app, over 33,000 text messages were sent by four London-based primary care centres inviting adults with loss of smell and/or taste in the preceding month to participate in the study. Participants wanted to be enrolled in the study were directed to a web-based platform, developed and hosted by Dendrite.
Once on the platform, participants were asked a series of questions to assess their eligibility, as well as having access to information on the study design, patient information sheets etc. After their eligibility was verified, participants then completed the on-line consent form and received a confirmation message. They then entered their contact and GP details, and the central Dendrite Registry then automatically sent a letter to the patient’s GP to confirm enrolment in the study.
Participants were then sent a point-of-care COVID19 testing kit. If a positive test was recorded, the central Dendrite Registry automatically issued a letter to the patient and the patient’s GP, and also automatically issued a letter to the patient’s GP when the study was completed.
The study was funded by the National Institute for Health Research Biomedical Research Centre at UCLH.
To access this paper, please click here
